FDA Approves Revuforj® as First Menin Inhibitor for Acute Leukemia with KMT2A Translocation

CHMP Recommends Approval of Opdivo® Plus Yervoy® for First-Line Treatment of MSI-H/dMMR Metastatic Colorectal Cancer

ADDF Invests $1.18M to Standardize p-tau217 Blood Tests for Alzheimer’s Diagnosis

GSK Reports Positive Interim Results for DREAMM-7 Trial of Blenrep in Multiple Myeloma

Molbio Diagnostics Invests $30 Million in OptraSCAN to Revolutionize Digital Pathology

BioNTech Acquires Chinese Oncology Firm Biotheus for $950M

The Care and Protection of Children Trust

CPCT Launches Groundbreaking Initiative to Provide Lifelong Free Treatment for Children with Spinal Muscular Atrophy (SMA) in Karnataka

Early Comprehensive Genomic Profiling Improves Cancer Treatment Outcomes, Study Shows

EMA Reverses Decision, Recommends Limited Approval for Eisai and Biogen’s Alzheimer’s Drug Leqembi

Exact Sciences Unveils Advances in Multi-Cancer Early Detection with Cancerguard™ Test

MSD and LaNova Medicines Enter Exclusive Global License Agreement for Novel Cancer Therapy, LM-299

Promising CAR T Cell Therapies from BMS and Cabaletta Bio Show Potential for Durable Remission in Severe Lupus

FDA Grants Accelerated Approval to PTC Therapeutics' KEBILIDI™, the First Gene Therapy for AADC Deficiency in the U.S.

Association for Molecular Pathology Publishes Joint Consensus Report on SARS-CoV-2 Genomic Surveillance for Hospitals and Public Health Laboratories

Philips India Unveils Advanced Azurion Imaging System to Revolutionize Cardiac and Neurovascular Care

Home
/
insight
/
details

What is companion diagnostics ?

NextEdge Admin

18 Nov 2023

2 min 47 sec

Companion diagnostics (CDx) refer to a type of medical test or diagnostic tool that is used to identify specific characteristics of a patient’s disease at themolecular or genetic level. These diagnostics are closely linked, or “companion,” to a particular medical treatment or therapy. The primary purpose of companion diagnostics is to assist healthcare professionals in tailoring treatments to individual patients, ensuring that they receive the most appropriate and effective therapy.

Here are some key points about companion diagnostics:

Personalized Medicine: Companion diagnostics are an essential component of personalized or precision medicine, which aims to customize medical treatments based on a patient’s unique genetic or molecular profile. By identifying specific biomarkers or genetic mutations associated with a disease, doctors can choose treatments that are more likely to work for that patient, minimizing potential side effects and optimizing outcomes.
Targeted Therapies: CDx tests are often used in conjunction with targeted therapies, which are medications designed to interact with specific molecular targets within the body. These drugs are often more effective and less harmful than traditional chemotherapy or other non-targeted treatments.

Regulatory Approval: In many cases, companion diagnostics are developed and validated alongside the corresponding therapeutic drug. Both the drug and the CDx test are then submitted for regulatory approval as a package. The U.S. Food and Drug Administration (FDA) and other regulatory agencies evaluate these companion diagnostic tests to ensure they are accurate, reliable, and provide valuable information for treatment decisions.
Improved Outcomes: Companion diagnostics have the potential to improve patient outcomes by ensuring that treatments are more precisely matched to the underlying biology of the disease. This can lead to better response rates and reduced side effects.